Academic Journal
A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia
| Title: | A Survival Analysis of Patients with Recurrent Epithelial Ovarian Cancer Based on Relapse Type: A Multi-Institutional Retrospective Study in Armenia |
|---|---|
| Authors: | Lilit Harutyunyan, Evelina Manvelyan, Nune Karapetyan, Samvel Bardakhchyan, Aram Jilavyan, Gevorg Tamamyan, Armen Avagyan, Liana Safaryan, Davit Zohrabyan, Narine Movsisyan, Anna Avinyan, Arevik Galoyan, Mariam Sargsyan, Martin Harutyunyan, Hasmik Nersoyan, Arevik Stepanyan, Armenuhi Galstyan, Samvel Danielyan, Armen Muradyan, Gagik Jilavyan |
| Source: | Current Oncology, Vol 31, Iss 3, Pp 1323-1334 (2024) |
| Publisher Information: | MDPI AG, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: | recurrent ovarian cancer, platinum-sensitive relapse, platinum-resistant relapse, platinum-refractory relapse, targeted therapy, chemotherapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: | Background: Annually, approximately 200 new ovarian cancer cases are diagnosed in Armenia, which is considered an upper-middle-income country. This study aimed to summarize the survival outcomes of patients with relapsed ovarian cancer in Armenia based on the type of recurrence, risk factors, and choice of systemic treatment. Methods: This retrospective case-control study included 228 patients with relapsed ovarian cancer from three different institutions. Results: The median age of the patients was 55. The median follow-up times from relapse and primary diagnosis were 21 and 48 months, respectively. The incidence of platinum-sensitive relapse was 81.6% (186), while platinum-resistant relapse was observed in only 18.4% (42) of patients. The median post-progression survival of the platinum-sensitive group compared to the platinum-resistant group was 54 vs. 25 months (p < 0.001), respectively, while the median survival after relapse was 25 vs. 13 months, respectively; three- and five-year post-progression survival rates in these groups were 31.2% vs. 23.8%, and 15.1% vs. 9.5%, respectively (p = 0.113). Conclusions: Overall, despite new therapeutic approaches, ovarian cancer continues to be one of the deadly malignant diseases affecting women, especially in developing countries with a lack of resources, where chemotherapy remains the primary available systemic treatment for the majority of patients. Low survival rates demonstrate the urgent need for more research focused on this group of patients with poor outcomes. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 1718-7729 1198-0052 |
| Relation: | https://www.mdpi.com/1718-7729/31/3/100; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729 |
| DOI: | 10.3390/curroncol31030100 |
| Access URL: | https://doaj.org/article/786ec4df7f0149208daeb599b2e0349e |
| Accession Number: | edsdoj.786ec4df7f0149208daeb599b2e0349e |
| Database: | Directory of Open Access Journals |
| Full text is not displayed to guests. | Login for full access. |
| ISSN: | 17187729 11980052 |
|---|---|
| DOI: | 10.3390/curroncol31030100 |
| Published in: | Current Oncology |
| Language: | English |